Escitalopram and paroxetine in the treatment of generalised anxiety disorder

Author:

Baldwin David S.,Huusom Anna Karina Trap,Mæhlum Eli

Abstract

BackgroundIt is uncertain whether higher doses of selective serotonin reuptake inhibitors have greater efficacy in generalised anxiety disorder.AimsTo assess the efficacy of different doses of escitalopram in generalised anxiety disorder.MethodRandomised, double-blind, placebo-controlled, fixed-dose, parallel-group, 12-week study, with 681 patients: placebo (n=139); escitalopram, 5 mg/day, (n=134); 10 mg/day (n=136); 20 mg/day (n=133); paroxetine, 20 mg/day (n=139).ResultsMean change in the primary efficacy measure was greater with escitalopram 10 and 20 mg than with placebo; 10 mg was more efficacious than paroxetine. Paroxetine was superior to placebo on some secondary measures, at sometime points. Compared with placebo, more patients withdrew because of adverse events with escitalopram 20 mg and paroxetine.ConclusionsEscitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day Escitalopram 10 mg was more efficacious than paroxetine.

Publisher

Royal College of Psychiatrists

Subject

Psychiatry and Mental health

Reference26 articles.

1. World Medical Association (2000) Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. http://www.wma.net/e/policy/b3.htm

2. A modelling strategy for the analysis of clinical trials with partly missing longitudinal data

3. The Mini International Neuropsychiatric Interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM–IV and ICD–10;Sheehan;Journal of Clinical Psychiatry,1998

4. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

5. Paroxetine Treatment of Generalized Anxiety Disorder: A Double-Blind, Placebo-Controlled Study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3